Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$723000.0.

  • Enanta Pharmaceuticals' Change in Account Payables rose 5299.09% to -$723000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 21666.67%. This contributed to the annual value of -$1.3 million for FY2025, which is 21666.67% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Change in Account Payables is -$723000.0, which was up 5299.09% from -$1.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Change in Account Payables high stood at $6.6 million for Q1 2023, and its period low was -$5.1 million during Q2 2022.
  • Its 5-year average for Change in Account Payables is -$226894.7, with a median of -$686000.0 in 2022.
  • In the last 5 years, Enanta Pharmaceuticals' Change in Account Payables soared by 179620.85% in 2021 and then tumbled by 292333.33% in 2022.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Account Payables (Quarter) stood at -$1.7 million in 2021, then surged by 58.75% to -$686000.0 in 2022, then surged by 854.23% to $5.2 million in 2023, then crashed by 103.25% to -$168000.0 in 2024, then crashed by 330.36% to -$723000.0 in 2025.
  • Its Change in Account Payables stands at -$723000.0 for Q3 2025, versus -$1.3 million for Q2 2025 and $873000.0 for Q1 2025.